Results 11 to 20 of about 2,007,940 (182)

Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring. [PDF]

Journal of Infectious Diseases, 2023
BACKGROUND Confounding introduced by individuals' sexual risk behavior is potentially a significant source of bias in HIV-1 prevention intervention studies.
Zakir Gaffoor, Arendevi Pather, Francis Martinson   +2 more
exaly   +4 more sources

Packing Polymorphism of Dapivirine and Its Impact on the Performance of a Dapivirine-Releasing Silicone Elastomer Vaginal Ring [PDF]

Journal of Pharmaceutical Sciences, 2017
A silicone elastomer vaginal ring providing sustained release over 28 days of the anti-retroviral microbicide dapivirine has recently completed phase III clinical testing and showed moderate protection against HIV acquisition. In support of the product licensure program, we report the impact of dapivirine packing polymorphism on the thermal and ...
Patrick Spence, Clare McCoy, Diarmaid Murphy   +2 more
exaly   +6 more sources

The impact of an educational intervention on undergraduate students’ knowledge, acceptability, and willingness to pay for dapivirine vaginal ring in Nigeria's first indigenous university: a single-arm, non-randomized study [PDF]

Discover Social Science and Health
Background This study aimed to assess the impact of an educational intervention on knowledge, acceptability, and willingness to pay (WTP) for dapivirine vaginal ring (DPV-VR) by undergraduate female students at the University of Nigeria (UNN).
Abdulmuminu Isah, Gabriel Ezenri, Ogechi Obi, Nnamdi A. Okibe, Hadiza Usman Ma’aji, Ezinwanne J. Ugochukwu, Cynthia C. Eze, Chisom M. Amoke, Augustus Ezeodimegwu, Charles C. Idabor, Mustapha Muhammed Abubakar, Francis Iloabuchi, Ikenna John Ugwu, Chukwuebuka M. Asogwa, Chinwe V. Ukwe, Blessing Onyinye Ukoha-kalu   +15 more
doaj   +3 more sources

Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women [PDF]

New England Journal of Medicine, 2016
The incidence of human immunodeficiency virus (HIV) infection remains high among women in sub-Saharan Africa. We evaluated the safety and efficacy of extended use of a vaginal ring containing dapivirine for the prevention of HIV infection in 1959 healthy, sexually active women, 18 to 45 years of age, from seven communities in South Africa and Uganda.In
Patrick Spence, Linda-Gail Bekker, Sylvia Kusemererwa   +2 more
exaly   +8 more sources

Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel [PDF]

International Journal of Pharmaceutics: X, 2021
A dapivirine-releasing silicone elastomer vaginal ring for reducing women's risk of HIV acquisition has recently been approved. A next-generation multipurpose vaginal ring releasing dapivirine and levonorgestrel is currently in development, offering ...
Yahya H. Dallal Bashi, Diarmaid J. Murphy, Clare F. McCoy, Peter Boyd, Leeanne Brown, Matthew Kihara, François Martin, Nicole McMullen, Kyle Kleinbeck, Bindi Dangi, Patrick Spence, Bashir Hansraj, Brid Devlin, R. Karl Malcolm   +13 more
doaj   +5 more sources

Incremental value of non-pharmacokinetic adherence measures for dapivirine vaginal ring use in resource limited setting [PDF]

Trials
Background Measuring product use adherence remains a challenge in HIV prevention trials and routine care setting. We determined agreement among and between non-pharmacokinetic (non-PK) and pharmacokinetic (PK) adherence measures, and also assessed the ...
Andrew Max Abaasa, Sylvia Kusemererwa
doaj   +3 more sources

Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring. [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Breastfeeding (BF) women are an important population for biomedical HIV prevention strategies, but they are rarely included in trials. The 25-mg dapivirine vaginal ring (VR) reduced women’s risk of sexually transmitted HIV infection in two phase 3 trials conducted in Africa.
Jeanna Piper, Lisa Noguchi, Craig W Hendrix   +2 more
exaly   +7 more sources

Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence. [PDF]

AIDS Behav
Product adherence is critical to obtaining objective estimates of efficacy of pre-exposure prophylactic interventions against HIV-1 infection. With imperfect adherence, intention-to-treat analyses assess the collective effects of complete, sub-optimal ...
Husnik MJ, Heffron R, Hughes JP, Richardson B, van der Straten A, Palanee-Phillips T, Soto-Torres L, Singh D, Mirembe BG, Livant E, Gaffoor Z, Mansoor LE, Siva SS, Dadabhai S, Kiweewa FM, Baeten JM, MTN-020/ASPIRE Study Team.   +16 more
europepmc   +4 more sources

“People have options”: a qualitative study of experiences and influences of PrEP choice among women in South Africa [PDF]

Journal of the International AIDS Society
Introduction Long‐acting injectable cabotegravir and dapivirine vaginal ring were recently introduced in South Africa through demonstration projects, providing additional HIV prevention options to oral pre‐exposure prophylaxis (PrEP). PrEP choice marks a
Siphokazi Dada, Faith Mary Musvipwa, Fatima Abegail Cholo, Melanie Pleaner, Alison Kutywayo, Vusile Butler, Catherine Elizabeth Martin, Saiqa Mullick   +7 more
doaj   +3 more sources

Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027) [PDF]

BMC Public Health
Background/aims The dapivirine vaginal ring is a self-administered, women-initiated, discreet, long-acting HIV-1 prevention option for women. It was found to be safe and effective in healthy HIV-negative women who adhered to product use instructions, and
Cecilia Milford, Hariska Ramlal, Rorisang Mofokeng, Letitia Rambally Greener, Annaléne Nel, Jennifer Smit, Mariëtte Malherbe   +6 more
doaj   +3 more sources